satralizumab (Enspryng) Report issue

Biologics mAb Orphan Drug FDA Approved FDA Fast Track FDA Breakthrough Therapy FDA
AACT

Active Ingredient History

NOW
  • Now

Chemistry

More Chemistry

Pharmacology

Drug Pricing (per unit)

United States

$11108.3000 - $14541.9500
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

sa237

Organizations (6)

Research & Development (6)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (2)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (8)

Approved Indications (1)


 

Neuromyelitis Optica (approved 2020)

Experimental Indications - Clinical Trial Phases 1-4 (8)


 

Autoimmune Diseases of the Nervous System (Phase 3)

Brain Ischemia (Early Phase 1)

Graves Ophthalmopathy (Phase 3)

Myasthenia Gravis (Phase 3)

Myelin-Oligodendrocyte Glycoprotein (Phase 3)

Neuromyelitis Optica (Phase 4)

Pulmonary Arterial Hypertension (Phase 2)

Subarachnoid Hemorrhage (Early Phase 1)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 12
  • # of Trial Organizations: 6

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue